Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | DAO | P14920 | 1/20 | 0.34 |
| ▸ | PLAU | P00749 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3830735 | 0.80 | ALDH1A1 (0.35) | ALDH1A1KDM4EPOLBHTTKMT2A | |
| SCHEMBL3830239 | 0.80 | ALDH1A1 (0.43) | ALDH1A1KDM4EHTTKMT2AMEN1 | |
| SCHEMBL29804248 | 0.80 | ALDH1A1 (0.43) | ALDH1A1KDM4EHTTKMT2AMEN1 | |
| SCHEMBL23754190 | 0.80 | ALDH1A1 (0.43) | ALDH1A1KDM4EHTTKMT2AMEN1 | |
| SCHEMBL17508469 | 0.80 | PLAU (0.36) | ALDH1A1KDM4EPOLBHTTKMT2A | |
| SCHEMBL677211 | 0.77 | RECQL (0.41) | ALDH1A1KDM4EPOLBHTTKMT2A | |
| SCHEMBL20298343 | 0.75 | KDM4E (0.38) | ALDH1A1KDM4EPOLBHTTKMT2A | |
| SCHEMBL22586961 | 0.72 | ALDH1A1 (0.43) | ALDH1A1KDM4EPOLBHTTKMT2A | |
| SCHEMBL25021454 | 0.72 | KDM4E (0.36) | ALDH1A1KDM4EPOLBHTTKMT2A | |
| SCHEMBL18956948 | 0.72 | KDM4E (0.36) | ALDH1A1KDM4EPOLBHTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220098154-A1 | ACETAMIDO DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | IDEAYA BIOSCIENCES, INC. | 2022-03-31 | — | — | US | disclosed |
| EP-3917627-A1 | ACETAMIDO DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | Ideaya Biosciences, Inc. (US) | 2021-12-08 | — | — | EP | disclosed |
| WO-2020160134-A1 | ACETAMIDO DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | IDEAYA BIOSCIENCES, INC. (US) | 2020-08-06 | — | — | WO | disclosed |
| WO-2020160134-A1 | ACETAMIDO DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | IDEAYA BIOSCIENCES, INC. (US) | 2020-08-06 | — | — | WO | disclosed |
| WO-2017201683-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS GPR120 AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-11-30 | — | — | WO | disclosed |
| WO-2016118586-A1 | LOWCOST, HIGH YIELD SYNTHESIS OF NEVIRAPINE | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2016-07-28 | — | — | WO | disclosed |
| WO-2016021742-A1 | HETEROCYCLIC COMPOUNDS AS EP4 RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-02-11 | — | — | WO | disclosed |
| US-8071776-B2 | Thienopyridines as allosteric potentiators of the M4 muscarinic receptor | ELI LILLY AND COMPANY (US) | 2011-12-06 | — | — | US | disclosed |
| EP-1807434-B1 | THIENOPYRIDINES AS ALLOSTERIC POTENTIATORS OF THE M4 MUSCARINIC RECEPTOR | LILLY CO ELI (US) | 2010-08-25 | — | — | EP | disclosed |
| EP-1999110-B1 | PROCESS FOR PREPARING l-HALO-2,7-NAPHTHYRIDINYL DERIVATIVES | UCB PHARMA SA (BE) | 2009-09-16 | — | — | EP | disclosed |
| US-20090105244-A1 | THIENOPYRIDINES AS ALLOSTERIC POTENTIATORS OF THE M4 MUSCARINIC RECEPTOR | ELI LILLY AND COMPANY (US) | 2009-04-23 | — | — | US | disclosed |
| EP-1999110-A2 | PROCESS FOR PREPARING l-HALO-2,7-NAPHTHYRIDINYL DERIVATIVES | UCB Pharma, S.A. (BE) | 2008-12-10 | — | — | EP | disclosed |
| WO-2007107345-A2 | PROCESS FOR PREPARING l-HALO-2,7-NAPHTHYRIDINYL DERIVATIVES | UCB PHARMA, S.A. (BE) | 2007-09-27 | — | — | WO | disclosed |
| EP-1807434-A1 | THIENOPYRIDINES AS ALLOSTERIC POTENTIATORS OF THE M4 MUSCARINIC RECEPTOR | ELI LILLY AND COMPANY (US) | 2007-07-18 | — | — | EP | disclosed |
| WO-2006047124-A1 | THIENOPYRIDINES AS ALLOSTERIC POTENTIATORS OF THE M4 MUSCARINIC RECEPTOR | ELI LILLY AND COMPANY (US) | 2006-05-04 | — | — | WO | disclosed |
| EP-0163894-B1 | COMPOSITE MATERIAL | BASF Aktiengesellschaft (DE) | 1990-11-14 | — | — | EP | disclosed |
| US-4764397-A | Fiber-reinforced materials | BASF AKTIENGESELLSCHAFT (DE) | 1988-08-16 | — | — | US | disclosed |
| US-4649080-A | Fiber-reinforced materials | BASF AKTIENGESELLSCHAFT (DE) | 1987-03-10 | — | — | US | disclosed |
| EP-0187348-A2 | Fibrous composite material | BASF Aktiengesellschaft (DE) | 1986-07-16 | — | — | EP | disclosed |
| EP-0163894-A2 | Composite material | BASF Aktiengesellschaft (DE) | 1985-12-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220098154-A1 | ACETAMIDO DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | POLQ, POLH, POLB | ALDH1A1 894/4885KDM4E 3875/4885POLB 3/4885 |
| US-20090105244-A1 | THIENOPYRIDINES AS ALLOSTERIC POTENTIATORS OF THE M4 MUSCARINIC RECEPTOR | CHRM2, CHRM4, CHRM1 | ALDH1A1 2594/4885KDM4E 4056/4885POLB 3715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.